<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vera Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/vera-therapeutics-inc</link>
<description>Latest news and press releases for Vera Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vera-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d23478dffbe2df1200b0.webp</url>
<title>Vera Therapeutics Inc</title>
<link>https://6ix.com/company/vera-therapeutics-inc</link>
</image>
<item>
<title>Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-appoints-jane-wright-mitchell-as-chief-legal-officer</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-appoints-jane-wright-mitchell-as-chief-legal-officer</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing</description>
</item>
<item>
<title>Vera Therapeutics Appoints Christopher Hite to Board of Directors</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-appoints-christopher-hite-to-board-of-directors-72</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-appoints-christopher-hite-to-board-of-directors-72</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing</description>
</item>
<item>
<title>Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-provides-business-update-and-reports-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-provides-business-update-and-reports-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings</description>
</item>
<item>
<title>Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-appointment-matt-123000128</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-appointment-matt-123000128</guid>
<pubDate>Wed, 28 Jan 2026 12:30:00 GMT</pubDate>
<description>BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. “We are pleased to welcome Matt to the executive</description>
</item>
<item>
<title>Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-inducement-grants-180500472</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-inducement-grants-180500472</guid>
<pubDate>Fri, 09 Jan 2026 18:05:00 GMT</pubDate>
<description>BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Ind</description>
</item>
<item>
<title>Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-participate-44th-annual-123000668</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-participate-44th-annual-123000668</guid>
<pubDate>Thu, 08 Jan 2026 12:30:00 GMT</pubDate>
<description>BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-on</description>
</item>
<item>
<title>Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-u-fda-123000045</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-u-fda-123000045</guid>
<pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
<description>FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN. BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today annou</description>
</item>
<item>
<title>Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-pricing-public-offering-class-common-stock-2025-12-10</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-pricing-public-offering-class-common-stock-2025-12-10</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on</description>
</item>
<item>
<title>Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-proposed-public-offering-class-common-stock-2025-12-08</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-proposed-public-offering-class-common-stock-2025-12-08</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on</description>
</item>
<item>
<title>Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-its-board</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-its-board</guid>
<pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Vera Therapeutics to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-participate-upcoming-investor-conferences-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-participate-upcoming-investor-conferences-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-participate-td-cowen-immunology-inflammation-summit-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-participate-td-cowen-immunology-inflammation-summit-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-submits-biologics-license-application-us-fda-through-accelerated</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-submits-biologics-license-application-us-fda-through-accelerated</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim</description>
</item>
<item>
<title>Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-positive-origin-phase-3-data-atacicept-iga-nephropathy</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-positive-origin-phase-3-data-atacicept-iga-nephropathy</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and</description>
</item>
<item>
<title>Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary</description>
</item>
<item>
<title>Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-host-investor-call-and-webcast-provide-origin-3-update-november-6</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-host-investor-call-and-webcast-provide-origin-3-update-november-6</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-origin-3-late-breaking-abstract-selected-featured-oral</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-announces-origin-3-late-breaking-abstract-selected-featured-oral</guid>
<pubDate>Fri, 17 Oct 2025 04:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-provides-business-reports-110000383</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-provides-business-reports-110000383</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026Announced positive primary endpoint results from the ongoing ORIGIN Phase 3 trialInitiated the PIONEER trial to investigate atacicept in a broader IgAN patient cohort and multiple autoimmune glomerular diseasesExpected to present full primary endpoint results from the ORIGIN 3 trial at a medical congress in Q4 2025 BRISBANE, Calif., Aug. 05, 20</description>
</item>
<item>
<title>Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-07</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-07</guid>
<pubDate>Thu, 10 Jul 2025 04:00:00 GMT</pubDate>
<description>BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee</description>
</item>
<item>
<title>Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-participate-goldman-sachs-46th-annual-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/vera-therapeutics-inc/news/vera-therapeutics-participate-goldman-sachs-46th-annual-global-healthcare-conference</guid>
<pubDate>Wed, 04 Jun 2025 04:00:00 GMT</pubDate>
<description>BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing</description>
</item>
</channel>
</rss>